Fulcrum Therapeutics (FULC.Q) announced positive results today from its ongoing Phase 1 trial with FTX-6058 in healthy adult volunteers. “We are very pleased with the interim results from this…
Latest News
Top 5 Gainers and Losers: KASH.CN, QIMC.CN, TGH.V
Zentek (ZEN.V) took a years long path to figure out its incredible biotech potential
Tesla stock to $100?
Top 5 Gainers and Losers: KASH.CN, DHR.V, BRO.V
Standard Uranium (STND.V) looks to add to Sun Dog’s uranium history
Top 5 Gainers and Losers: SEI.V, LAB.V, NCU.TO